You may know this from the headlines, but GLP-1 receptor agonists aren’t new.
They’ve been used in smaller doses in type 2 diabetes care for nearly two decades. That’s 20 years of real-world use and long-term safety data related to blood sugar control and cardiovascular risk in people with diabetes.
The approval for chronic weight management has a shorter history. And that word - chronic - matters.
Because that approval is more recent, data beyond four years is still being collected. Durability of weight loss, cardiovascular outcomes and rare side effects over longer periods continue to be monitored.
Still, large clinical trials show that many people who remain on the GLP-1 receptor agonists maintain meaningful weight loss and see improvements in metabolic health. That isn’t trivial.
There’s also a consistent pattern across studies: when the medication is stopped, weight regain is common.
No surprises there. These medications mimic the natural GLP-1 hormone and influence appetite and metabolic signaling. When the medication is removed, that influence is reduced. The underlying biology hasn’t changed.
Which brings us back to chronic.
For some individuals, clinicians increasingly view GLP-1 medications as life-long treatments, similar to those used for blood pressure or cholesterol.
That doesn’t eliminate the possibility of eventually weaning off. For some people, with sustained lifestyle and behavioral changes, thoughtful exit strategies can be considered.
Either way, with chronic conditions, the real question isn’t about speed.
It’s about long-term planning.
